Palliative communications: Addressing chemotherapy in patients with advanced cancer

Annals of Oncology

Volumn 23, Issue SUPPL.3, 2012, Pages 29-32

  Kadakia, K C ^a   Moynihan, T J ^a   Smith, T J ^b   Loprinzi, C L ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Goals of care; Honest communication; Palliative chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; INTERPERSONAL COMMUNICATION; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; PATIENT CARE; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; COMMUNICATION; HUMANS; MEDICAL FUTILITY; NEOPLASMS; PALLIATIVE CARE; PHYSICIAN-PATIENT RELATIONS; TERMINAL CARE; TRUTH DISCLOSURE;

EID: 84861748832     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds085     Document Type: Conference Paper

References (26)

1. Loprinzi CL, Schapira L, Moynihan T et al. Compassionate honesty. J Palliat Med 2010; 13: 1187-1191.
2. Smith TJ. The art of oncology: when the tumor is not the target. Tell it like it is. J Clin Oncol 2000; 18: 3441-3445.
3. Helft PR. Necessary collusion: prognostic communication with advanced cancer patients. J Clin Oncol 2005; 23: 3146-3150.
4. Innes S, Payne S. Advanced cancer patients' prognostic information preferences: a review. Palliat Med 2009; 23: 29-39.
5. Jiang Y, Liu C, Li JY et al. Different attitudes of Chinese patients and their families toward truth telling of different stages of cancer. Psychooncology 2007; 16: 928-936.
6. Kutner JS, Steiner JF, Corbett KK et al. Information needs in terminal illness. Soc Sci Med 1999; 48: 1341-1352.
7. Thompson GN, Chochinov HM, Wilson KG et al. Prognostic acceptance and the well-being of patients receiving palliative care for cancer. J Clin Oncol 2009; 27: 5757-5762.
8. Grunfeld E, Lethbridge L, Dewar R et al. Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med 2006; 20: 769-777.
9. Daniel L, Fakhouri F, Joly D et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney Int 2006; 69: 1416-1423.
10. Collins R, Fenwick E, Trowman R et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007; 11: iii-iv, xv-xviii, 1-179.
11. Liu S, Wang D, Chen B et al. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the firstline treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2011; 73: 203-210.
12. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New Engl J Med 2010; 363: 733-742.
13. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14: 671-679.
14. Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 2011; 29: 456-463.
15. Robinson TM, Alexander SC, Hays M et al. Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis. Support Care Cancer 2008; 16: 1049-1057.
16. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009; 101: 1174-1181.
17. Belkora JK, Hutton DW, Moore DH, Siminoff LA. Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication? J Natl Compr Cancer Netw 2011; 9: 707-712.
18. Samuel TA, Subbannan K. Horns of a dilemma. J Clin Oncol 2008; 26: 2219-2220; discussion 2221-2212.
19. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-1460.
20. Steensma DP. Submitting to autonomy. J Clin Oncol 2000; 18: 3736-3737.
21. Keating NL, Landrum MB, Rogers SO, Jr. et al. Physician factors associated with discussions about end-of-life care. Cancer 2010; 116: 998-1006.
22. Spettell CM, Rawlins WS, Krakauer R et al. A comprehensive case management program to improve palliative care. J Palliat Med 2009; 12: 827-832.
23. Keating NL, Beth Landrum M, Arora NK et al. Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol 2010; 28: 4364-4370.
24. Smith TJ, Dow LA, Virago E et al. Giving honest information to patients with advanced cancer maintains hope. Oncology 2010; 24: 521-525.
25. Mack JW, Wolfe J, Cook EF et al. Hope and prognostic disclosure. J Clin Oncol 2007; 25: 5636-5642.
26. Epner DE, Ravi V, Baile WF. When patients and families feel abandoned. Support Care Cancer 2011; 19: 1713-1717.